Alle Aktivitäten

J Dermatolog Treat. 2025 Dec;36(1):2474507. doi: 10.1080/09546634.2025.2474507. Epub 2025 Mar 6. ABSTRACT BACKGROUND: Emerging research suggests that Janus kinase-signal transducer and activator of transcription (JAK-STAT) inhibitors may be associated with a higher risk of serious infection for patients with rheumatoid arthritis. However, there is no consensus on whether JAK inhibitors increase the risk of serious infection in patients with Immune-mediated inflammatory skin diseases (IMISDs). OBJECTIVES: To ascertain the correlation between JAK inhibitor use and the risk of serious infection in patients with IMISDs. METHODS: PubMed, Cochrane Central Register of Controlled Trials (CENTRAL), and registered Clinical Trials were searched up to June 1, 2024, using specific search terms related to JAK inhibitors and IMISDs. Randomized clinical trials (RCTs) comparing JAK inhibitors with a control group in patients with IMISDs were included. Studies focusing on cohort studies, case reports, case series, review articles, pooled analysis studies, post hoc analyses and topical JAK inhibitors were excluded. Data were extracted independently by two authors, focusing on serious infections defined according to each study's criteria. Crude numbers for serious infections were pooled and underwent meta-analysis. We assessed the primary outcome regarding the occurrence of severe infections for each study. RESULTS: Thirty-two randomized clinical trials involving 11,917 patients were included. Serious infections were reported in 0.62% of patients receiving JAK inhibitors and 0.51% of controls. Meta-analysis found no significant increase in risk of serious infection (I2=0.00%, RR, 0.68; 95% CI, 0.43-1.07). Subgroup analyses revealed no significant heterogeneity based on condition (p = .56) or medication (p = .69). CONCLUSIONS: This meta-analysis demonstrates that JAK inhibitors do not significantly increase the risk of serious infections in IMISD patients compared to control treatments. These findings support the safety of JAK inhibitors in this population. Future research should focus on real-world evidence to further assess their risk-benefit profile in dermatological practice. PMID:40051127 | DOI:10.1080/09546634.2025.2474507 Den ganzen Artikel lesen

Display options Display options Purpose of review: In this narrative review, we provide an overview of how adherence to a Mediterranean dietary pattern …Den ganzen Artikel lesen

J Insur Med. 2025 Jul 1;52(1):3-5. doi: 10.17849/insm-52-1-3-5.1. ABSTRACT OBJECTIVE.—: To analyze a published study on all-cause mortality between psoriatic arthritis and matched population comparator-subjects to derive comparative mortality statistics applicable to life insurance underwriting. METHOD.—: The pixel method was employed for extracting cumulative survivals. It was chosen for its capability to extract data from published graphs despite potential precision and reliability limitations. RESULTS.—: The mortality analysis indicated an increase in mortality starting in year 4, aligning with the Table rating for Psoriatic arthritis. Pharmacological treatment data from the study revealed only 28% were on advanced therapies such as targeted synthetic or biologic DMARDs. This low percentage suggests most of the cohort had milder PsA, as advanced treatments are generally reserved for moderate to severe psoriatic arthritis. The distribution of treatment regimens provides essential insights into disease severity and its implications for mortality assessment. CONCLUSION.—: The comparative mortality findings correspond to Table rating for psoriatic arthritis. This finding underscores the importance of understanding treatment profiles and disease severity in life insurance underwriting to accurately assess risk. PMID:40047113 | DOI:10.17849/insm-52-1-3-5.1 Den ganzen Artikel lesen

Dermatol Reports. 2025 Mar 5. doi: 10.4081/dr.2025.10239. Online ahead of print. ABSTRACT Infantile hemangiomas are the most common soft-tissue tumors in children, with propranolol, a non-cardioselective β-blocker, considered the first-line treatment for complicated cases. β-blockers have been reported to be the most common causative agents for drug-induced psoriasis in adults. In the pediatric population, only one previous case exists. We report the case of a 12-month-old girl who developed a psoriasiform rash after starting oral propranolol for infantile hemangiomas on the scalp. The patient had no personal or family history of psoriasis, and the rash appeared one week post-initiation of propranolol, presenting as well-defined erythematous, scaly plaques over the body, including the scalp. Infectious causes were excluded, and the rash was diagnosed as a psoriasiform rash, possibly induced by oral propranolol. The patient was switched to atenolol, which resulted in improvement of the hemangioma and complete resolution of the skin lesions. This case highlights the rare but significant risk of psoriasiform eruptions associated with β-blocker therapy in infants, emphasizing the need for careful recognition and monitoring of this potential adverse effect in pediatric patients treated for infantile hemangiomas. PMID:40047218 | DOI:10.4081/dr.2025.10239 Den ganzen Artikel lesen

Dermatol Reports. 2025 Feb 6;17(1). doi: 10.4081/dr.2024.9999. Epub 2024 Aug 9. ABSTRACT Psoriasis is an inflammatory chronic disease of the skin, typically located on the extensor surfaces of the body and the trunk. Patients with psoriasis can often present multiple characteristics, such as lesions located in difficult-to-treat (DTT) areas or high severity of the disease, which can negatively affect their quality of life. There is a lack of consensus in identifying the best therapy for these complex patient populations, especially after the failure of one or multiple lines of therapy. In this regard, we report a case series describing patients with psoriasis located in different DTT areas or presenting a high Psoriasis Area and Severity Index (PASI) score at baseline and treated ineffectively with prior lines of therapy. Finally, patients achieved complete remission following therapy with tildrakizumab 200 mg (anti-IL-23p19), highlighting its potential efficacy in these patient populations. PMID:40047295 | DOI:10.4081/dr.2024.9999 Den ganzen Artikel lesen

Curr Nutr Rep. 2025 Mar 6;14(1):42. doi: 10.1007/s13668-025-00632-5. ABSTRACT PURPOSE OF REVIEW: In this narrative review, we provide an overview of how adherence to a Mediterranean dietary pattern can complement traditional treatment strategies for psoriasis, acne, and hidradenitis suppurativa. We emphasize the importance of an integrated approach, with dietary interventions as a key component of holistic patient care. RECENT FINDINGS: Psoriasis, acne, and hidradenitis suppurativa are immune-mediated chronic diseases marked by systemic inflammation, with genetic and environmental factors influencing their onset. The Mediterranean diet, rich in plant-based foods with antioxidant and anti-inflammatory properties-such as whole-grain cereals, extra-virgin olive oil, vegetables, legumes, fruits, and nuts-has been shown to reduce the clinical severity of these conditions. It also supports weight control and positively impacts metabolic and cardiovascular risk factors, which are closely linked to these diseases. Dietary education, particularly about the Mediterranean diet, plays a crucial role in the management of these skin diseases and serves as an important non-pharmacological treatment option that can influence patient prognosis. This review offers specific nutrition recommendations for prescribing the Mediterranean diet to patients with chronic inflammatory skin diseases. PMID:40048018 | DOI:10.1007/s13668-025-00632-5 Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2025 Mar 6. doi: 10.1007/s13555-024-01317-7. Online ahead of print. NO ABSTRACT PMID:40048065 | DOI:10.1007/s13555-024-01317-7 Den ganzen Artikel lesen

Adv Ther. 2025 Mar 6. doi: 10.1007/s12325-025-03138-2. Online ahead of print. ABSTRACT INTRODUCTION: Biosimilars allow more patients access to affordable treatment options and help reduce the financial burden on healthcare systems. This multicentre trial compared the efficacy, safety, and immunogenicity of the approved biosimilar ustekinumab FYB202 with reference ustekinumab. METHODS: Eligible patients were ≥ 18 years old with stable moderate-to-severe plaque psoriasis for ≥ 6 months and inadequate treatment response to or intolerance of ≥ 1 previous systemic treatment. Patients were randomised (1:1) to double-blind treatment with FYB202 or reference ustekinumab; patients in the reference group who achieved Psoriasis Area and Severity Index (PASI) 75 percent improvement at week 28 were re-randomised to FYB202 or reference product. The primary efficacy endpoint was percent improvement in PASI score from baseline to week 12. Therapeutic equivalence was demonstrated if, depending on the regulatory requirement with respect to the significance level, the two-sided 95% and 90% confidence intervals (CIs) were within the pre-defined equivalence intervals of ± 11% and ± 10%, respectively. RESULTS: A total of 392 patients were randomised to FYB202 (n = 197) or reference ustekinumab (n = 195). Baseline characteristics were well balanced between groups. Mean percent improvement in PASI score at week 12 was equivalent between FYB202 and reference ustekinumab with an estimated least-squares mean treatment difference of 3.27% and the two-sided 95% (- 0.90%, 7.44%) and 90% (- 0.22%, 6.77%) CIs fully contained within the pre-defined equivalence margins. Safety and immunogenicity profiles were comparable between groups. Switching from reference product to FYB202 had no clinically relevant effect on efficacy, safety, or immunogenicity. CONCLUSION: FYB202 demonstrated therapeutic equivalence to reference ustekinumab in patients with moderate-to-severe plaque psoriasis. TRIAL REGISTRATION: NCT04595409; EudraCT 2019-004364-21. PMID:40048101 | DOI:10.1007/s12325-025-03138-2 Den ganzen Artikel lesen

Dermatol Ther (Heidelb). 2025 Mar 6. doi: 10.1007/s13555-025-01370-w. Online ahead of print. ABSTRACT INTRODUCTION: Psoriasis is a chronic inflammatory skin disease affecting over 60 million people worldwide, often linked to comorbidities such as psoriatic arthritis and cardiovascular disease. Beyond physical symptoms, psoriasis can significantly impact major life-changing decisions (MLCDs), leading to long-term consequences and missed opportunities. This study focused on assessing MLCDs and their correlations with quality of life (QoL), disease acceptance, and itch severity, emphasizing the need for early intervention to mitigate cumulative life course impairment. METHODS: A total of 166 consecutive patients with psoriasis, comprising 101 men and 65 women, all with a minimum disease duration of 1 year, were included in the study. Clinical and psychological aspects of psoriasis were thoroughly evaluated using a range of standardized instruments, along with a questionnaire collecting demographic data. RESULTS: Psoriasis affected at least one MLCD in 93.4% of patients, most commonly influencing decisions related to physical activity (77%), dietary habits (70%), smoking and alcohol consumption (58%), and job choices (30%). A significant correlation was found between the Major Life-Changing Decisions Profile (MLCDP) total score and QoL (r = 0.561, p < 0.001), psoriasis severity (r = 0.275, p < 0.001), and itch severity (r = 0.351, p < 0.001), as well as an inverse correlation with disease acceptance (r = - 0.545, p < 0.001). CONCLUSION: Psoriasis may affect MLCDs, reflecting the long-term consequences of the disease. A comprehensive approach is essential to prevent these impacts, especially in cases of early-onset psoriasis. PMID:40050518 | DOI:10.1007/s13555-025-01370-w Den ganzen Artikel lesen

Gut Microbes. 2025 Dec;17(1):2473524. doi: 10.1080/19490976.2025.2473524. Epub 2025 Mar 6. ABSTRACT This review explores the emerging term "gut-skin axis" (GSA), describing the bidirectional signaling that occurs between the skin and the gastrointestinal tract under both homeostatic and disease conditions. Central to GSA communication are the gut and skin microbiota, the microbial communities that colonize these barrier surfaces. By influencing diverse host pathways, including innate immune, vitamin D receptor, and Aryl hydrocarbon receptor signaling, a balanced microbiota contributes to both tissue homeostasis and host defense. In contrast, microbiota imbalance, or dysbiosis at one site, can lead to local barrier dysfunction, resulting in the activation of signaling pathways that can disrupt tissue homeostasis at the other site, potentially leading to inflammatory skin conditions such as atopic dermatitis and psoriasis, or gut diseases like Inflammatory Bowel Disease. To date, most research on the GSA has examined the impact of the gut microbiota and diet on skin health, but recent studies show that exposing the skin to ultraviolet B-light can beneficially modulate both the gut microbiome and intestinal health. Thus, despite the traditional focus of clinicians and researchers on these organ systems as distinct, the GSA offers new opportunities to better understand the pathogenesis of cutaneous and gastrointestinal diseases and promote health at both sites. PMID:40050613 | DOI:10.1080/19490976.2025.2473524 Den ganzen Artikel lesen

BMC Womens Health. 2025 Mar 6;25(1):101. doi: 10.1186/s12905-025-03625-2. ABSTRACT BACKGROUND: Skin diseases are a category of chronic conditions that often impact patients' appearance, potentially leading to psychological issues, including sexual dysfunction. The present study is an attempt to determine the global prevalence of female sexual dysfunction (FSD) in women with skin diseases. METHODS: For this systematic review and meta-analysis, databases including PubMed, Web of Science, Scopus, Science Direct, Embase, and Google Scholar were systematically searched for relevant studies. All published research up to April 2024 imported into EndNote for further analysis. A random-effects model was applied for the analysis, and the I² statistic was used to assess study heterogeneity. RESULTS: Analysis of 24 studies (45 datasets) indicated that the overall prevalence of FSD in women with skin diseases was estimated at 61.3% (95% CI: 53.9-68.2%). Additionally, subgroup analysis based on skin disease type revealed an FSD prevalence of 69.8% (95% CI: 56.7-80.2%) in women with vitiligo, 59.2% (95% CI: 49.1-68.5%) in those with psoriasis, and 56.5% (95% CI: 47.8-64.8%) in women with hidradenitis suppurativa. CONCLUSION: There was a high prevalence of FSD in women with skin diseases. There is a need for policy makers and healthcare providers to prioritize the well-being of these patients. PMID:40050796 | DOI:10.1186/s12905-025-03625-2 Den ganzen Artikel lesen

Nat Commun. 2025 Feb 28;16(1):2051. doi: 10.1038/s41467-025-56719-8.ABSTRACTPsoriasis is a common, debilitating immune-mediated skin disease. Genetic …Den ganzen Artikel lesen

ZusammenfassungHintergrund und ZielePsoriasis vulgaris ist eine chronisch entzündliche Hauterkrankung, die mit zahlreichen kardiovaskulären …Den ganzen Artikel lesen

Hassan Moftah N, H Abbas Helmy W, Mohamed Elbakry A, Mohammed Gamal-Edeen A, Al-Sayed Al-Kady N. Hassan Moftah N, et al. Arch Dermatol Res. 2024 Dec …Den ganzen Artikel lesen

Background: Psoriasis is an inflammatory disease primarily treated through molecular-targeted therapies. However, emerging evidence suggests that …Den ganzen Artikel lesen

There is a direct link between psoriasis and metabolic conditions such as diabetes mellitus and obesity.1 Exercise of varied intensity in patients …Den ganzen Artikel lesen

Psoriasis and psoriatic arthritis are chronic inflammatory conditions that constitute a significant global health burden due to their prevalence and …Den ganzen Artikel lesen

1. Introduction Metabolic disorders, including type 2 diabetes mellitus (T2DM), obesity, and metabolic syndrome (MetS), pose significant global health …Den ganzen Artikel lesen

J Dermatol. 2025 Feb 3. doi: 10.1111/1346-8138.17645. Online ahead of print. ABSTRACT The association between psoriasis and streptococcal infection has been widely explored in both children and adults. However, the exact impact of Streptococcus pharyngeal infection on the course of psoriasis is not fully comprehended. This study explored the impact of Streptococcus pharyngeal infection on psoriasis and investigated the effectiveness of systemic antibiotic therapy in conjunction with standard topical treatment for psoriatic patients with concomitant streptococcal throat infection. The research involved 115 patients with mild-to-moderate psoriasis, clinically assessed using the Psoriasis Area and Severity Index (PASI). Patients with active streptococcal infection were administered adjunctive systemic antibiotic therapy along with standard local treatment for psoriasis, while psoriasis patients without evidence of infection received the local topical treatment only. Streptococcal infections were more common in psoriasis patients compared to healthy controls. A group of psoriasis patients with active streptococcal throat infections, treated with antibiotics in addition to standard topical psoriasis therapy, did not show any difference in PASI score reduction compared to those without evidence of active infection. While our study did not show a statistically significant reduction in PASI scores in psoriasis patients with streptococcal throat infections treated with antibiotics, it highlights the complex interaction between infection and psoriasis. Larger studies with longer follow-up may better clarify this relationship, contributing to stronger evidence for or against the use of antibiotics in managing psoriasis triggered by streptococcal infections. PMID:39895559 | DOI:10.1111/1346-8138.17645 Den ganzen Artikel lesen

Indian J Dermatol. 2025 Jan-Feb;70(1):42-46. doi: 10.4103/ijd.ijd_719_24. Epub 2024 Dec 30. ABSTRACT Behçet's disease is a chronic inflammatory condition that affects multiple organs and systems. It is characterized by recurrent oral and genital ulcers. A previous study reported that the IL-17A inhibitor secukinumab can improve the skin and mucosal manifestations in patients with refractory Behçet's disease. Additionally, secukinumab has been shown to effectively improve neurological symptoms when administered for Behçet's disease. However, we report a case where Behçet's disease occurred after the treatment of psoriasis with the IL-17A inhibitor ixekizumab. To summarize its clinical characteristics and treatment experience, we consulted relevant domestic and international literature and conducted a literature review. We concluded that anti-IL-17A treatment may lead to the development of Behçet's disease. The reported cases are more likely to occur in middle-aged men with varying onset times. The main manifestations include oral and vulvar mucosal ulcers. Furthermore, the gut microbiota may be involved in paradoxical Behçet's disease. PMID:39896301 | PMC:PMC11784972 | DOI:10.4103/ijd.ijd_719_24 Den ganzen Artikel lesen

Cureus. 2025 Jan 3;17(1):e76869. doi: 10.7759/cureus.76869. eCollection 2025 Jan. ABSTRACT While topical steroids are an invaluable tool used for the treatment of pruritic rashes, they can also complicate attempts at a definitive diagnosis. The temporal association between steroid use and biopsy must be taken into account when investigating the underlying etiology of such rashes. In patients with a history of dermatologic disease with the onset of a new rash, management should include a biopsy, if deemed necessary for diagnosis, followed by a prescription of topical steroids for symptomatic treatment. A 63-year-old male with a history of psoriasis presented with a new-onset pruritic, erythematous-to-violaceous rash on sun-exposed areas. The final diagnosis of subacute cutaneous lupus erythematosus (SCLE) was delayed due to the use of topical steroids on cutaneous eruptions before presentation in the clinic for biopsy. Diagnosis of SCLE can be difficult, especially for primary care providers who do not see the initial presentation regularly, as cutaneous findings can be variable in presentation. However, recurrent eruptions in similar photo-distributed locations should alert providers of a potential underlying diagnosis and prompt referral for dermatologic evaluation should be suggested. Thorough personal and family history should be taken and photographs of the rash should be documented in the patient's chart for future reference. Ultimately, biopsy is the gold standard diagnostic method for evaluating the etiology of new-onset rash. When there is suspicion of an underlying disease beyond idiopathic contact or irritant dermatitis, a biopsy should be considered as the next best step in management. PMID:39897333 | PMC:PMC11787870 | DOI:10.7759/cureus.76869 Den ganzen Artikel lesen

Ther Adv Musculoskelet Dis. 2025 Jan 31;17:1759720X251315138. doi: 10.1177/1759720X251315138. eCollection 2025. ABSTRACT BACKGROUND: Randomized clinical trials have demonstrated the efficacy of secukinumab (SECU) in reducing disease activity in psoriatic arthritis (PsA), while real-world studies prove a broader perspective on SECU's usefulness in everyday clinical practice. OBJECTIVES: To assess the effectiveness of SECU by evaluating drug survival and identifying potential predictors of clinical response and treatment discontinuation in patients with moderate-to-severe PsA, using real-world data from the Italian Group for the Study of Early Arthritis (GISEA) registry. DESIGN: This longitudinal retrospective study included PsA patients treated with SECU, spanning from May 2016 to November 2023. METHODS: Data from 1045 PsA patients, including 783 with peripheral-only PsA (perPsA) and 262 with peripheral and axial involvement (mixed PsA) were analyzed. Drug survival was estimated by Kaplan-Meier analysis. Clinical outcomes, including Disease Activity Index for Psoriatic Arthritis (DAPSA), Psoriasis Area Severity Index (PASI), Ankylosing Spondylitis Disease Activity Score (ASDAS, C-Reactive Protein (CRP)-based), and Visual Analogue Scale (VAS) measures, were evaluated at baseline and at 6, 12, and 24 months. Adjusted hazard ratios (aHRs) for discontinuing SECU were determined using multivariate Cox regression models. RESULTS: SECU survival at 24 months was 63.24%, significantly higher in mixed PsA compared to perPsA (p = 0.036). In the overall PsA population, DAPSA scores decreased significantly at 6 months, and further at 24 months (all p < 0.0001). In mixed PsA, ASDAS-CRP scores were significantly reduced at 6 months and remained stable through 24 months (all p < 0.0001). VAS pain scores also improved already at 6 months and continued to improve at 24 months (all p < 0.0001). Higher age (aHR = 0.98, 95% confidence interval (CI): 0.96-0.99, p = 0.007) and lower baseline DAPSA scores (aHR = 1.02, 95% CI: 1.01-1.03, p = 0.014) were associated with greater persistence of SECU treatment. SECU was well tolerated, with no serious adverse events. CONCLUSION: SECU showed sustained clinical improvements in both peripheral and axial involvement of PsA patients over 24 months, with higher persistence observed in mixed PsA patients. Our findings highlight the favorable clinical and safety profile of SECU in real world. PMID:39897378 | PMC:PMC11783553 | DOI:10.1177/1759720X251315138 Den ganzen Artikel lesen

SAGE Open Med Case Rep. 2025 Jan 31;13:2050313X251317763. doi: 10.1177/2050313X251317763. eCollection 2025. ABSTRACT Palmoplantar plaque psoriasis is more resistant to therapy compared to other phenotypes of psoriasis. To our knowledge, there are no reports of the efficacy of Janus kinase (JAK) inhibitors for palmoplantar plaque psoriasis. Two adult females presented with more than 6-year histories of severe palmoplantar plaque psoriasis. The first patient had failed topical therapies, phototherapy, acitretin, and secukinumab. The second patient had failed topical therapies and systemic agents including alitretinoin, cyclosporine, apremilast, ustekinumab, ixekizumab, and risankizumab. Both cases were switched to upadacitinib 15 mg daily, with a complete response by 3 months of therapy and no adverse events. The first patient had slightly elevated fasting triglyceride and the second patient had elevated ALT, both of which are being monitored. This case series highlights the efficacy of upadacitinib in two patients with refractory palmoplantar plaque psoriasis. JAK1 inhibitors may be considered as third-line therapeutic options in patients with refractory palmoplantar plaque psoriasis and no contraindications to JAK inhibitors. PMID:39897569 | PMC:PMC11786266 | DOI:10.1177/2050313X251317763 Den ganzen Artikel lesen

JAAD Int. 2024 Nov 14;19:12-20. doi: 10.1016/j.jdin.2024.09.015. eCollection 2025 Apr. ABSTRACT BACKGROUND: There is limited evidence on treating psoriasis patients with skin of color (SOC), contributing to disparities in accessing appropriate care for these patients. OBJECTIVES: This study aimed to develop consensus statements defining SOC terminology and addressing needs to optimize the clinical management of psoriasis in patients with SOC. METHODS: Using the modified Delphi methodology 16 Canadian dermatologists with expertise in psoriasis developed consensus statements. Four core faculty members drove the content of the study, and 12 additional panel members were consulted to vote and provide consensus on the content produced by the core faculty. At a final meeting, the full panel revised and voted on the final consensus statements. RESULTS: The exercise resulted in 11 consensus statements on SOC terminology, as well as 5 primary and 4 secondary statements on clinical presentation and differential diagnosis, and treatment guidelines based on evidence and expert opinion. Four additional consensus statements on current assessment tools and access to care were developed based solely on expert opinion. LIMITATIONS: The available evidence was limited, low quality, and inappropriate for formal quality assessment. CONCLUSIONS: The consensus statements developed in this study may provide valuable guidance to the dermatology community treating psoriasis patients with SOC. PMID:39898016 | PMC:PMC11783118 | DOI:10.1016/j.jdin.2024.09.015 Den ganzen Artikel lesen

Int J Med Sci. 2025 Jan 1;22(3):558-564. doi: 10.7150/ijms.102434. eCollection 2025. ABSTRACT Background: Recent studies suggest a potential link between HS and renal dysfunction. Our objective is to assess the correlation between hidradenitis suppurativa (HS) and renal consequences, specifically focusing on acute kidney injury (AKI), chronic kidney disease (CKD), and end-stage renal disease (ESRD). Methods: This study was performed based on retrospective cohort design. Electronic medical records of participants were retrieved from the US collaborative network in the TriNetX research network. Information from 46,561 individuals with HS was examined alongside an equivalent number of matched controls. Propensity matching was performed for matching confounders. The study spanned from January 1, 2005, to December 31, 2017. Primary outcomes were set as renal dysfunction, including AKI, CKD, and ESRD. Results: Over the 1-year follow-up, people with HS presented a 1.84-fold higher risk of AKI (95% CI, 1.34-2.53) and a 1.37-fold higher risk of CKD (95% CI, 1.02-1.85) than non-HS individuals. Elevated risks persisted over the longer follow-up periods for AKI at 1.51-fold (95% CI, 1.28-1.77) for 3-years-follow-up and 1.47-fold (95% CI, 1.30-1.65) for 5-years-follow-up, respectively. Stratification by sex revealed higher risks in males, and comparison with psoriasis patients indicated increased AKI and CKD risks in HS patients. Conclusion: This study highlights a significant association between HS and renal dysfunction, emphasizing the need for further exploration of shared pathophysiological mechanisms. The findings could offer potential insights into HS-related comorbidities. PMID:39898256 | PMC:PMC11783075 | DOI:10.7150/ijms.102434 Den ganzen Artikel lesen